Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging
Movement Disorders Clinical Practice · 2023-04 · 10 (4) · 539-546
DOI: 10.1002/mdc3.13687 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 17.02.2023. Verfasst von Nicholas Heng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Neuroscience and Psychology University of Glasgow Glasgow Scotland UK. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, Allergan, ASAP.
Abstract (Originalsprache)
Background
Neuropathological studies, based on small samples, suggest that symptoms of Parkinson's disease (PD) emerge when dopamine/nigrostriatal loss is around 50–80%. Functional neuroimaging can be applied in larger numbers during life, which allows analysis of the extent of dopamine loss more directly.
Objective
To quantify dopamine transporter (DaT) activity by neuroimaging in early PD.
Methods
Systematic review and novel analysis of DaT imaging studies in early PD.
Results
In our systematic review, in 423 unique cases from 27 studies with disease duration of less than 6 years, mean age 58.0 (SD 11.5) years, and mean disease duration 1.8 (SD 1.2) years, striatal loss was 43.5% (95% CI 41.6, 45.4) contralaterally, and 36.0% (95% CI 33.6, 38.3) ipsilaterally. For unilateral PD, in 436 unique cases, mean age 57.5 (SD 10.2) years, and mean disease duration 1.8 (SD 1.4) years, striatal loss was 40.6% (95% CI 38.8, 42.4) contralaterally, and 31.6% (95% CI 29.4, 33.8) ipsilaterally. In our novel analysis of the Parkinson's Progressive Marker Initiative study, 413 cases had 1436 scans performed. For a disease duration of less than 1 year, age was 61.8 (SD 9.8) years, and striatal loss was 51.2% (95% CI 49.1, 53.3) contralaterally and 39.5% (36.9, 42.1) ipsilaterally, giving an overall striatal loss of 45.3% (43.0, 47.6).
Conclusions
Loss of striatal DaT activity in early PD is less at 35–45%, rather than the 50–80% striatal dopamine loss estimated to be present at the time of symptom onset, based on backwards extrapolation from autopsy studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Neuroscience and Psychology University of Glasgow Glasgow Scotland UK.
- Department of Neurology Queen's Hospital Romford Essex UK.
- Population Health Sciences, Bristol Medical School University of Bristol Bristol UK.
ORCID-Profile: Nicholas Heng, Vanessa Pitz
Förderung
- AbbVie
- Allergan
- ASAP
- Avid Radiopharmaceuticals
- Biogen
- Bristol Myers Squibb
- Celgene
- Denali Therapeutics
Zitieren
APA
Heng, N., Malek, N., Lawton, M. A., Nodehi, A., Pitz, V., Grosset, K. A., Ben-Shlomo, Y., & Grosset, D. G. (2023). Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging. Movement Disorders Clinical Practice, 10(4), 539-546. https://doi.org/10.1002/mdc3.13687
Vancouver
Heng N, Malek N, Lawton MA, Nodehi A, Pitz V, Grosset KA, et al. Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging. Movement Disorders Clinical Practice. 2023;10(4):539-546. doi:10.1002/mdc3.13687
BibTeX
@article{Heng2023,
author = {Heng, Nicholas and Malek, Naveed and Lawton, Michael A and Nodehi, Anahita and Pitz, Vanessa and Grosset, Katherine A and Ben-Shlomo, Yoav and Grosset, Donald G},
title = {Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging},
journal = {Movement Disorders Clinical Practice},
year = {2023},
volume = {10},
number = {4},
pages = {539--546},
doi = {10.1002/mdc3.13687}
}
EUVIMED